AstraZeneca Reports Results of Imfinzi (durvalumab) in P-III CASPIAN Study for 1L Extensive-Stage Small Cell Lung Cancer

Shots:

• The P-III CASPIAN study involves assessing of Imfinzi + etoposide with cisplatin/carboplatin CT or Imfinzi + tremelimumab +CT vs CT as monothx. consisting of up to six cycles of CT and optional prophylactic cranial irradiation (PCI) in patients with extensive-stage SCLC in 22+ countries
•  The P-III CASPIAN study results: median OS (13.0 vs 10.3 mos.); OS rate @18mos. (33.9% vs 24.7%); PFS rate @12 mos. (17.5% vs 4.7%); ORR (67.9% vs 57.6%); DoR @12mos. (22.7% vs 6.3%)
• Imfinzi is a mAb targeting PD-L1, blocking its interaction with PD-1 and CD80, countering the tumor’s immune-evading tactics and releasing the inhibition of immune responses and is an approved therapy for advanced bladder cancer in 10 countries, including the US

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Coroflot